Vistagen Q1 FY27 net loss $13.0M; cash $31.7M; FDA meeting planned for fasedienol path

Vistagen Therapeutics, Inc.

Net loss $13.0M for Q1 ended June 30, 2026, vs $15.1M year-ago; revenue $1.2M from Fuji Pharma exclusivity expiration.
Cash, equivalents and marketable securities $31.7M; sufficient into 2027 but not beyond one year from now.
PALISADE-4 missed primary endpoint overall; post-hoc very severe SAD subpopulation showed nominally significant improvement vs placebo.
FDA meeting planned this quarter to discuss potential Phase 3 registrational path for fasedienol in social anxiety disorder.
Appointed Angel S. Angelov, M.D., MBA as CMO and Douglas J. Williamson, M.D. to Board; FDA 'Study May Proceed' for refisolone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.